| Abstract: |
The age-adjusted International Prognostic Index assessed before salvage therapy with ICE (ifosfamide, carboplatin, etoposide) predicts outcome in patients with relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL). Patients can be stratified according to this index into favorable and unfavorable cohorts. Subsequently we attempted to determine if the cell of origin as determined by immunohistochemistry would predict outcome, as it had in the first-line setting. However, none of the molecular markers, which are prognostic in first-line therapy, nor immunohistochemical classification by cell of origin, relate to survival outcome of DLBCL patients in the second-line setting, implying that dose intensification of therapy can overcome the prognostic import of these unfavourable risk factors. © 2006 Oxford University Press. |
| Keywords: |
immunohistochemistry; cancer survival; treatment outcome; survival rate; treatment failure; prednisone; salvage therapy; doxorubicin; conference paper; combined modality therapy; rituximab; drug megadose; follow up; antineoplastic agent; ki 67 antigen; carboplatin; protein bcl 2; neoplasm recurrence, local; etoposide; antineoplastic combined chemotherapy protocols; tumor markers, biological; cohort analysis; cyclophosphamide; vincristine; autologous stem cell transplantation; stem cell transplantation; protein p53; prediction; risk factor; ifosfamide; b cell lymphoma; lymphoma, b-cell; cancer regression; nonhodgkin lymphoma; prognostic factors; long term care; cancer relapse; dna microarray; protein bcl 6; large cell lymphoma; mucin 1; mesna; granulocyte colony stimulating factor; transplantation, autologous; common acute lymphoblastic leukemia antigen; lymphoma, large-cell, diffuse; diffuse large b-cell lymphoma (dlbcl); ice (ifosfamide, carboplatin, etoposide) regimen; multidrug resistance protein
|
